We are analyzing https://link.springer.com/article/10.1007/s10549-005-6939-z.

Title:
Nordihydroguaiaretic Acid (NDGA) Inhibits the IGF-1 and c-erbB2/HER2/neu Receptors and Suppresses Growth in Breast Cancer Cells | Breast Cancer Research and Treatment
Description:
Nordihydroguaiaretic acid (NDGA) is a phenolic compound isolated from the creosote bush Larrea divaricatta that has anti-cancer activities both in vitro and in vivo. We can now attribute certain of these anti-cancer properties in breast cancer cells to the ability of NDGA to directly inhibit the function of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu (HER2/neu) receptor. In MCF-7 human breast cancer cells, low micromolar concentrations of NDGA inhibited activation of the IGF-1R, and downstream phosphorylation of both the Akt/PKB serine kinase and the pro-apoptotic protein BAD. In mouse MCNeuA cells, NDGA also inhibited ligand independent phosphorylation of HER2/neu. To study whether this inhibitory effect in cells was due to a direct action on these receptors, we studied the IGF-1-stimulated tyrosine kinase activity of isolated IGF-1R, which was inhibited by NDGA at 10 μM or less. NDGA was also effective at inhibiting autophosphorylation of the isolated HER2/neu receptor at similar concentrations. In addition, NDGA inhibited IGF-1 specific growth of cultured breast cancer cells with an IC50 of approximately 30 μM. NDGA treatment (intraperitoneal injection 3 times per week) also decreased the activity of the IGF-1R and the HER2/neu receptor in MCNeuA cells implanted into mice. This inhibition of RTK activity was associated with decreased growth rates of MCNeuA cells in vivo. These studies indicate that the anti-breast cancer properties of NDGA are related to the inhibition of two important RTKs. Agents of this class may therefore provide new insights into potential therapies for this disease.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

google, scholar, cas, pubmed, cancer, article, growth, breast, receptor, cells, cell, insulinlike, factor, human, kinase, res, ndga, acid, tyrosine, apoptosis, nordihydroguaiaretic, inhibition, mice, inhibitors, research, receptors, access, biol, treatment, igf, herneu, activity, factors, pancreatic, oncogene, privacy, cookies, content, inhibits, youngren, activation, protein, expression, usa, transgenic, lipoxygenase, san, publish, search, goldfine,

Topics {✒️}

c-erbb2/her2/neu receptors month download article/chapter growth factor receptors lipoxygenase inhibitor-induced apoptosis pro-apoptotic protein bad physiologically relevant target mmtv/neu transgenic mouse garcia-echeverria ma pearson fujita-yamaguchi js miller cardiff wj muller c-erbb2/her2/neu sbraccia id goldfine triple-negative breast cancer igf2-id1-igf2 circuit high-performance liquid chromatography anti-breast cancer properties cozens db evans full article pdf akt/pkb serine kinase lobo lj esserman protein tyrosine phosphorylation isolated her2/neu receptor antiapoptotic signalling tyrosine kinase inhibitors san francisco/mt human breast cancer breast cancer cells colorectal tumor cells klippel mj weber seufferlein mj seckl mouse mcneua cells growth factor receptor transgenic mice expressing transgenic mice carrying arteaga receptor tyrosine kinases protein kinase article youngren breast cancer stem molecular ullrich wl mcguire normoglycemic pima indians receptors anti-cancer properties privacy choices/manage cookies malignant glioma cells dyal1mxlvvyhs7c%3d 10 dyal1mxmt1kjs78%3d 10 dyak1cxksfkksrk%3d 10 malkinson jl mulshine

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Nordihydroguaiaretic Acid (NDGA) Inhibits the IGF-1 and c-erbB2/HER2/neu Receptors and Suppresses Growth in Breast Cancer Cells
         description:Nordihydroguaiaretic acid (NDGA) is a phenolic compound isolated from the creosote bush Larrea divaricatta that has anti-cancer activities both in vitro and in vivo. We can now attribute certain of these anti-cancer properties in breast cancer cells to the ability of NDGA to directly inhibit the function of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu (HER2/neu) receptor. In MCF-7 human breast cancer cells, low micromolar concentrations of NDGA inhibited activation of the IGF-1R, and downstream phosphorylation of both the Akt/PKB serine kinase and the pro-apoptotic protein BAD. In mouse MCNeuA cells, NDGA also inhibited ligand independent phosphorylation of HER2/neu. To study whether this inhibitory effect in cells was due to a direct action on these receptors, we studied the IGF-1-stimulated tyrosine kinase activity of isolated IGF-1R, which was inhibited by NDGA at 10 μM or less. NDGA was also effective at inhibiting autophosphorylation of the isolated HER2/neu receptor at similar concentrations. In addition, NDGA inhibited IGF-1 specific growth of cultured breast cancer cells with an IC50 of approximately 30 μM. NDGA treatment (intraperitoneal injection 3 times per week) also decreased the activity of the IGF-1R and the HER2/neu receptor in MCNeuA cells implanted into mice. This inhibition of RTK activity was associated with decreased growth rates of MCNeuA cells in vivo. These studies indicate that the anti-breast cancer properties of NDGA are related to the inhibition of two important RTKs. Agents of this class may therefore provide new insights into potential therapies for this disease.
         datePublished:
         dateModified:
         pageStart:37
         pageEnd:46
         sameAs:https://doi.org/10.1007/s10549-005-6939-z
         keywords:
            MCF-7 cells
            proliferation
            small molecule inhibitor
            syngeneic mouse model
            tyrosine kinase
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:94
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jack F. Youngren
               affiliation:
                     name:University of California
                     address:
                        name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Karissa Gable
               affiliation:
                     name:University of California
                     address:
                        name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cristina Penaranda
               affiliation:
                     name:University of California
                     address:
                        name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Betty A. Maddux
               affiliation:
                     name:University of California
                     address:
                        name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marianna Zavodovskaya
               affiliation:
                     name:University of California
                     address:
                        name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Margaret Lobo
               affiliation:
                     name:University of California
                     address:
                        name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael Campbell
               affiliation:
                     name:University of California
                     address:
                        name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John Kerner
               affiliation:
                     name:University of California
                     address:
                        name:Department of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ira D. Goldfine
               affiliation:
                     name:University of California
                     address:
                        name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Nordihydroguaiaretic Acid (NDGA) Inhibits the IGF-1 and c-erbB2/HER2/neu Receptors and Suppresses Growth in Breast Cancer Cells
      description:Nordihydroguaiaretic acid (NDGA) is a phenolic compound isolated from the creosote bush Larrea divaricatta that has anti-cancer activities both in vitro and in vivo. We can now attribute certain of these anti-cancer properties in breast cancer cells to the ability of NDGA to directly inhibit the function of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu (HER2/neu) receptor. In MCF-7 human breast cancer cells, low micromolar concentrations of NDGA inhibited activation of the IGF-1R, and downstream phosphorylation of both the Akt/PKB serine kinase and the pro-apoptotic protein BAD. In mouse MCNeuA cells, NDGA also inhibited ligand independent phosphorylation of HER2/neu. To study whether this inhibitory effect in cells was due to a direct action on these receptors, we studied the IGF-1-stimulated tyrosine kinase activity of isolated IGF-1R, which was inhibited by NDGA at 10 μM or less. NDGA was also effective at inhibiting autophosphorylation of the isolated HER2/neu receptor at similar concentrations. In addition, NDGA inhibited IGF-1 specific growth of cultured breast cancer cells with an IC50 of approximately 30 μM. NDGA treatment (intraperitoneal injection 3 times per week) also decreased the activity of the IGF-1R and the HER2/neu receptor in MCNeuA cells implanted into mice. This inhibition of RTK activity was associated with decreased growth rates of MCNeuA cells in vivo. These studies indicate that the anti-breast cancer properties of NDGA are related to the inhibition of two important RTKs. Agents of this class may therefore provide new insights into potential therapies for this disease.
      datePublished:
      dateModified:
      pageStart:37
      pageEnd:46
      sameAs:https://doi.org/10.1007/s10549-005-6939-z
      keywords:
         MCF-7 cells
         proliferation
         small molecule inhibitor
         syngeneic mouse model
         tyrosine kinase
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:94
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jack F. Youngren
            affiliation:
                  name:University of California
                  address:
                     name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Karissa Gable
            affiliation:
                  name:University of California
                  address:
                     name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cristina Penaranda
            affiliation:
                  name:University of California
                  address:
                     name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Betty A. Maddux
            affiliation:
                  name:University of California
                  address:
                     name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marianna Zavodovskaya
            affiliation:
                  name:University of California
                  address:
                     name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Margaret Lobo
            affiliation:
                  name:University of California
                  address:
                     name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael Campbell
            affiliation:
                  name:University of California
                  address:
                     name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John Kerner
            affiliation:
                  name:University of California
                  address:
                     name:Department of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ira D. Goldfine
            affiliation:
                  name:University of California
                  address:
                     name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:94
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of California
      address:
         name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Department of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jack F. Youngren
      affiliation:
            name:University of California
            address:
               name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Karissa Gable
      affiliation:
            name:University of California
            address:
               name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Cristina Penaranda
      affiliation:
            name:University of California
            address:
               name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Betty A. Maddux
      affiliation:
            name:University of California
            address:
               name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Marianna Zavodovskaya
      affiliation:
            name:University of California
            address:
               name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Margaret Lobo
      affiliation:
            name:University of California
            address:
               name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Michael Campbell
      affiliation:
            name:University of California
            address:
               name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:John Kerner
      affiliation:
            name:University of California
            address:
               name:Department of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Ira D. Goldfine
      affiliation:
            name:University of California
            address:
               name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
      name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
      name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
      name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
      name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
      name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
      name:Department of Surgery, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
      name:Department of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA
      name:Division of Diabetes and Endocrine Research, San Francisco/Mt. Zion Medical Center, University of California, San Francisco, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(201)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.99s.

LINK . SPRINGER . COM {}